Supplementary Table 1. Summary of adverse events in atogepant and placebo groups

Adverse events	Dose	Studies reported (n)	The incidence rate in the atogepant group (event/total, %)	The incidence rate in the placebo group (event/total, %)
Any TEAE	10.00 mg (QD)	2	178/314, 56.70%	218/408, 53.40%
	30.00 mg (QD)	2	234/411, 57.00%	218/408, 53.40%
	60.00 mg (QD)	3	312/573, 54.45%	302/565, 53.45%
	30.00 mg (BID)	1	52/86, 60.40%	92/186, 49.50%
	60.00 mg (BID)	1	53/91, 58.24%	92/186, 49.50%
Treatment-related TEAE	10.00 mg (QD)	2	68/314, 21.65%	50/408, 12.25%
	30.00 mg (QD)	2	73/411, 17.76%	50/408, 12.25%
	60.00 mg (QD)	3	100/573, 17.45%	64/565, 11.33%
	30.00 mg (BID)	1	18/86, 20.90%	30/186, 16.10%
	60.00 mg (BID)	1	24/91, 26.40%	30/186, 16.10%
SAEs	10.00 mg (QD)	2	3/314, 0.95%	4/408, 0.98%
	30.00 mg (QD)	2	2/411, 0.49%	4/408, 0.98%
	60.00 mg (QD)	3	6/573, 1.05%	4/565, 0.70%
	30.00 mg (BID)	1	0/86, 0.00%	2/186, 1.07%
	60.00 mg (BID)	1	0/91, 0.00%	2/186, 1.07%
TEAEs leading to treatment discontinuation	10.00 mg (QD)	1	9/221, 4.10%	6/222, 2.70%
	30.00 mg (QD)	1	4/228, 1.80%	6/222, 2.70%
	60.00 mg (QD)	2	9/387, 2.33%	8/379, 2.11%
Constipation	10.00 mg (QD)	2	19/314, 6.05%	5/408, 1.23%
	30.00 mg (QD)	2	26/411, 6.33%	5/408, 1.23%
	60.00 mg (QD)	3	41/573, 7.15%	9/565, 1.59%
	30.00 mg (BID)	1	3/86, 3.49%	4/186, 2.15%
	60.00 mg (BID)	1	4/91, 4.40%	4/186, 2.15%
Nausea	10.00 mg (QD)	2	16/314, 5.09%	13/408, 3.19%
	30.00 mg (QD)	2	23/411, 5.60%	13/408, 3.19%
	60.00 mg (QD)	3	47/573, 8.20%	18/565, 3.18%
	30.00 mg (BID)	1	8/86, 9.30%	9/186, 4.84%
	60.00 mg (BID)	1	9/91, 9.90%	9/186, 4.84%
UTIs	10.00 mg (QD)	2	5/314, 1.60%	12/408, 2.94%
	30.00 mg (QD)	2	20/411, 4.86%	12/408, 2.94%
	60.00 mg (QD)	3	18/573, 3.14%	16/565, 2.80%
	30.00 mg (BID)	1	2/86, 2.33%	4/186, 2.15%
	60.00 mg (BID)	1	3/91, 3.30%	4/186, 2.15%
Nasopharyngitis	10.00 mg (QD)	2	7/314, 2.23%	12/408, 2.94%
	30.00 mg (QD)	2	19/411, 4.62%	12/408, 2.94%
	60.00 mg (QD)	3	30/573, 5.33%	24/565, 4.25%
	30.00 mg (BID)	1	1/86, 1.16%	4/186, 2.15%
	60.00 mg (BID)	1	3/91, 3.30%	4/186, 2.15%
URTIs	10.00 mg (QD)	2	15/314, 4.80%	25/408, 6.13%
	30.00 mg (QD)	2	27/411, 6.57%	25/408, 6.13%
	60.00 mg (QD)	2	19/417, 4.56%	25/408, 6.13%
	30.00 mg (BID)	1	6/86, 6.97%	15/186, 8.06%
	60.00 mg (BID)	1	6/91, 6.59%	15/186, 8.06%
Fatigue	10.00 mg (QD)	2	4/314, 1.27%	10/408, 2.45%
	30.00 mg (QD)	2	10/411, 2.43%	10/408, 2.45%

(Continued to the next page)

Supplementary Table 1. Continued

Adverse events	Dose	Studies reported (n)	The incidence rate in the atogepant group (event/total, %)	The incidence rate in the placebo group (event/total, %)
	60.00 mg (QD)	2	14/417, 3.35%	10/408, 2.45%
	30.00 mg (BID)	1	2/86, 2.33%	6/186, 3.23%
	60.00 mg (BID)	1	9/91, 9.90%	6/186, 3.23%
Increased blood creatine kinase level	10.00 mg (QD)	2	9/314, 2.86%	5/408, 1.23%
	30.00 mg (QD)	2	5/411, 1.22%	5/408, 1.23%
	60.00 mg (QD)	2	9/417, 2.16%	5/408, 1.23%
	30.00 mg (BID)	1	6/86, 6.97%	3/186, 1.60%
	60.00 mg (BID)	1	2/91, 2.19%	3/186, 1.60%
Death	10.00 mg (QD)	1	0/221, 0.00%	0/222, 0.00%
	30.00 mg (QD)	1	0/228, 0.00%	0/222, 0.00%
	60.00 mg (QD)	2	0/387, 0.00%	0/379, 0.00%
Somnolence	10.00 mg (QD)	1	7/221, 3.20%	2/222, 0.90%
	30.00 mg (QD)	1	4/228, 1.80%	2/222, 0.90%
	60.00 mg (QD)	1	4/231, 1.70%	2/222, 0.90%
Sinusitis	10.00 mg (QD)	1	4/221, 1.80%	3/222, 1.40%
	30.00 mg (QD)	1	3/228, 1.30%	3/222, 1.40%
	60.00 mg (QD)	1	5/231, 2.20%	3/222, 1.40%
Gastroenteritis	10.00 mg (QD)	1	2/221, 0.90%	4/222, 1.80%
	30.00 mg (QD)	1	5/228, 2.20%	4/222, 1.80%
	60.00 mg (QD)	1	3/231, 1.30%	4/222, 1.80%
Increase alanine aminotransferase level	10.00 mg (QD)	1	3/221, 1.40%	6/222, 2.70%
	30.00 mg (QD)	1	2/228, 0.90%	6/222, 2.70%
	60.00 mg (QD)	1	2/231, 0.90%	6/222, 2.70%
Influenza	10.00 mg (QD)	1	3/221, 1.40%	2/222, 0.90%
	30.00 mg (QD)	1	2/228, 0.90%	2/222, 0.90%
	60.00 mg (QD)	1	5/231, 2.20%	2/222, 0.90%
Sinus congestion	10.00 mg (QD)	1	1/221, 0.50%	5/222, 2.30%
	30.00 mg (QD)	1	2/228, 0.90%	5/222, 2.30%
	60.00 mg (QD)	1	4/231, 1.70%	5/222, 2.30%
Increased aspartate aminotransferase level	10.00 mg (QD)	1	2/221, 0.90%	6/222, 2.70%
	30.00 mg (QD)	1	2/228, 0.90%	6/222, 2.70%
	60.00 mg (QD)	1	1/231, 0.40%	6/222, 2.70%
Anxiety	10.00 mg (QD)	1	2/221, 0.90%	2/222, 0.90%
	30.00 mg (QD)	1	1/228, 0.40%	2/222, 0.90%
	60.00 mg (QD)	1	5/231, 2.20%	2/222, 0.90%

TEAE, treatment-related treatment-emergent adverse event; SAE, serious adverse event; UTI, urinary tract infection; URTI, upper respiratory tract infection; QD, once daily; BID, twice a day.